- Details
- In this conversation, Alicia Morgans and Rosalind Eeles discuss how patients should be selected for genetic counseling and testing. This discussion highlights several important questions including: What is the spectrum of genetic predisposition that we currently know? How should we use this? Who should be tested? Are there international discrepancies in the guidelines? How do we manage men who are...
|
- Details
- During the Molecular Biomarkers and Novel Imaging in Advanced Prostate Cancer session at the Advanced Prostate Cancer Consensus Conference (APCCC 2019), Dr. Rosalind Eeles discussed how patients should be selected for genetic counseling and testing. She highlights several key points for clinicians to consider when thinking through how we should think about which men should be tested for genetic ab...
|
- Details
- Eli Van Allen shares details on The Metastatic Prostate Cancer Project, a project part of a larger nationwide genomic research project called "Count Me In" for men with advanced or metastatic prostate cancer. The Metastatic Prostate Cancer Project takes a new approach to cancer research in which researchers partner directly with men with metastatic and/or advanced prostate cancer, who share their...
|
- Details
- In the era that genomics and genetics are really making an impact to clinical practice and with the recent positive results of the PROfound study, Alicia Morgans and Colin Pritchard have a discussion thinking about this data, how do we implement it, and how do we work with our pathologists to make things happen? Colin highlights this game-changing genomic markers data, particularly for homologous...
|
- Details
- Jacob Berchuck, MD and Mary-Ellen Taplin, MD join Alicia Morgans in discussing areas of genetic risk in high-risk localized prostate cancer. They discuss the complexity of screening patients and incorporating the identifying of patients for genetic risk into clinical workflow. Jacob shares details on a collaboration with Mark Pomerantz at Dana-Farber and Phil Kantoff at Memorial Sloan Kettering, a...
|
- Details
- Sarah Abou Alaiwi, MD discusses her recently presented bench to bedside research with Monty Pal, MD. She explains that PBRM1 is frequently mutated around 40% on Renal Cell Carcinoma. It is part of this Mammalian SWI/SNF complex, which is really what drove interest in this complex. This complex is really huge. It has 29 subunits. It's frequently mutated in around 20% of all human cancers. There is...
|
- Details
- Alicia Morgans discusses genetic counseling in GU cancers with Brittany Szymaniak. This conversation includes the challenges, the benefits, the concerns of genetic testing and how this is accomplished in clinical practice for people who have genital urinary malignancies, so prostate cancer, bladder cancer, kidney cancer. They also discuss the family syndromes for men with prostate cancer that shou...
|
- Details
- Wassim Abida provides a current roadmap for molecular genetic subtyping in prostate cancer with the main goal of targeting the right therapies for progressing patients. The one clear indication for molecular testing at this point is in the identification of MSI-high prostate cancer because pembrolizumab is approved for this indication. Investigational PARP inhibitors (poly (ADP-ribose) polymerase...
|
- Details
- Elena Castro discusses the role of BRCA-2 mutations and the risk of developing prostate cancer. BRCA-2 germline carriers have an increased risk of developing prostate cancer representing a ~30% lifetime rate of developing prostate cancer. Patients with BRCA-2 mutations tend to develop more aggressive prostate cancer and typically present with lymph node involvement or distant metastases. Based on...
|
- Details
- Elena Castro, MD discusses her recent publication in Journal Clinical Oncology on DNA repair defects in prostate cancer. The primary objective of the study was to determine whether mutations in BRCA 1, BRCA 2, ATM and PALB 2 would affect survival in patients diagnosed with mCRPC. A panel of 107 genes was analyzed. Patients who were carrying these mutations, in particular, BRCA2, had shorter surviv...
|
